Skip to main content
Premium Trial:

Request an Annual Quote

Biobase and Incyte; Inproteo and Indiana University Kelley School of Business, Qiagen and Australian Proteome Analysis Facility, and National Institutes of Health

Premium

Biobase Acquires Incyte’s Proteome Data Business

German bioinformatics firm Biobase said this week that it has acquired Proteome, a subsidiary of Incyte, for an undisclosed amount.

Proteome, located in Beverly, Mass., produces the BioKnowledge Library, a six-volume database containing information about proteins, particularly pharmaceutically relevant targets and signaling pathways.

Biobase said that the acquisition broadens its biological database product line, and that the incorporation of Proteome’s US offices is expected to triple Biobase’s size. Biobase will, however, maintain its headquarters in Wolfenbuttel, Germany.

The transaction was financed by a fund managed by private equity firm Avida.


Inproteo Signs Up Indiana University Business Students to Commercialize Proteomics Device

Inproteo and the Indiana University Kelley School of Business have founded a new company, to be run by students and faculty, to help commercialize new proteomics tools.

The first product will be an automated sample loader for proteomics research, developed at Eli Lilly and licensed to Inproteo. Shot, a company based in Greenville, Ind., will develop a prototype, which the new company, to be housed at the Indiana University Research Park in Bloomington, expects to bring to market later this year.

Inproteo is a consortium between Eli Lilly, Indiana University, and Purdue University that aims to license new proteomics technologies or spin them off into new companies.


Qiagen, Australian Proteome Analysis Facility Partner to Develop Sample-Prep Tools

Qiagen and the Australian Proteome Analysis Facility plan to co-develop new proteomic sample preparation tools, APAF said this week.

Over the next three years, researchers at APAF will work with Qiagen to develop new tools and methods to reduce the complexity of samples prior to analyzing their proteins.

APAF, a government-funded research organization, is headquartered at Macquarie University in Sydney.


NIH Earmarks $1 Million for Research Into Therapies Using Genomic, Proteomic Technologies

The National Institutes of Health issued last week a request for applications for projects designed to support “the career development of translational researchers in genomics.”

According to the NIH, it will award three-, four-, and five-year grants of between $150,000 and $230,000 to “clinicians who propose an integrated clinical research and bench research project that applies genomics and proteomics tools to the study of human patients whose disease has a genetic component.” This includes “the application of increasing knowledge of the genome and the proteome to the development and implementation of novel therapeutic strategies as applied to genetic diseases and complex diseases with a genetic component,” the NIH said.

According to the NIH, the funding will be awarded under the institute’s K23 mechanism, which “requires an integrated clinical-laboratory research project that directly involves patients affected by the disease being studied so that awardees can develop skills in both clinical research and basic science; [and] emphasizes career development and a research program that focuses on developing effective therapeutic interventions.” Additionally, this mechanism “requires significant utilization of genomic and proteomic tools and technologies in the research project,” the NIH said.

The NIH said it anticipates awarding four to six grants under this RFA.

Letters of intent from applicants are due by May, 16. Applications are due by June 15. Additional details about the RFA can be found here.